Reply to letter to the editor: “The dosage of rifabutin in H. pylori eradication regimen should be appropriately determined in each area of the world”

Antzeko izenburuak

• World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat
  nork: Suzuki, Hidekazu, et al.
  Argitaratua: (2017)
• Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study
  nork: Mori, Hideki, et al.
  Argitaratua: (2015)
• Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: how should rifabutin be managed in rescue regimens?
  nork: Losurdo, Giuseppe, et al.
  Argitaratua: (2015)
• Acquisition of double mutation in gyrA caused high resistance to sitafloxacin in Helicobacter pylori after unsuccessful eradication with sitafloxacin-containing regimens
  nork: Mori, Hideki, et al.
  Argitaratua: (2017)
• Response to letter regarding: development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication
  nork: Hideki Mori, et al.
  Argitaratua: (2022-12-01)